A case of ovarian stimulation for fertility preservation in a patient with Philadelphia chromosome‐positive acute lymphoblastic leukemia after treatment with dasatinib
| Autor: | Maki Ogi, Tatsuyuki Ogawa, Shuji Hirata |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty 030219 obstetrics & reproductive medicine Philadelphia Chromosome Positive medicine.drug_class business.industry Obstetrics and Gynecology Hematopoietic stem cell Stimulation Tyrosine-kinase inhibitor Dasatinib 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure hemic and lymphatic diseases 030220 oncology & carcinogenesis Internal medicine Remission Induction Therapy medicine Fertility preservation business Tyrosine kinase medicine.drug |
| Zdroj: | Journal of Obstetrics and Gynaecology Research. 47:1182-1185 |
| ISSN: | 1447-0756 1341-8076 |
| DOI: | 10.1111/jog.14668 |
| Popis: | Tyrosine kinase inhibitors (TKIs) are effective for treating Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). However, the use of TKIs may decrease the number of collected oocytes during fertility preservation procedures. We report the case of a 19-year-old patient with Ph+ALL for whom 21 oocytes were frozen after controlled ovarian stimulation was initiated 2 days after the completion of 28 days of remission induction therapy with dasatinib. After collecting the oocytes, consolidation therapy was initiated immediately, and a hematopoietic stem cell transplant from her younger brother was scheduled. It is believed that a 2-day withdrawal period is sufficient for fertility preservation or that the effect of dasatinib on the number of oocytes obtained is minimal. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text